The FDA is expected to announce its decision on BioCryst Pharmaceuticals Inc.’s (BCRX) Orladeyo, proposed for the prevention of hereditary angioedema attacks, on December 3, 2020.In a phase III clinical trial, dubbed APeX-2, 50% of patients in the treatment arm of BCX7353 had a 70 percent or more than 70 percent reduction in their HAE attack rate from baseline compared to 15 percent in placebo arm.Orladeyo is also under review in Japan and Europe, with a decision expected in December and March, respectively. Currently, 7 products have secured FDA approval for preventing and treating HAE attacks and all these drugs are delivered intravenously or administered subcutaneously.Berinert, Firazyr, Kalbitor and Ruconest are approved for treating HAE attacks while Cinryze, Haegarda, and Takhzyro are approved for preventing HAE attacks. (Source: US HAEA)Orladeyo, if approved, will become the first oral treatment for preventing Hereditary Angioedema attacks.The global Hereditary Angioedema Therapeutics Market is expected to reach $4.2 billion by 2026, according to a new report by Grand View Research, Inc. BCRX closed Friday’s (Nov.27, 2020) trading at $5.13, up 7.77%.